Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
FEASIBILITY AND PHARMACOKINETICS OF CARBAMAZEPINE ORAL LOADING DOSES
Autore:
COHEN H; HOWLAND MA; LUCIANO DJ; RUBIN RN; KUTT H; HOFFMAN RS; LEUNG LKH; DEVINSKY O; GOLDFRANK LR;
Indirizzi:
KINGSBROOK JEWISH MED CTR,DEPT PHARMACEUT SERV,585 SCHENECTADY AVE BROOKLYN NY 11203 LONG ISL UNIV,ARNOLD & MARIE SCHWARTZ COLL PHARM & HLTH SCI GREENVALENY 00000 KINGSBROOK JEWISH MED CTR,CLIN PHARM SERV BROOKLYN NY 11203 KINGSBROOK JEWISH MED CTR,DEPT PHARM BROOKLYN NY 11203 KINGSBROOK JEWISH MED CTR,DEPT MED BROOKLYN NY 11203 NYU,MED CTR,DEPT EMERGENCY MED,BELLEVUE HOSP CTR NEW YORK NY 10016 NEW YORK CITY POISON CONTROL CTR NEW YORK NY 00000 HOSP JOINT DIS & MED CTR,INST ORTHOPAED,COMPREHENS EPILEPSY CTR,CLIN EPILEPSY CTR NEW YORK NY 00000 NYCPCC,BUR LABS NEW YORK NY 00000 NEW YORK CITY DEPT HLTH NEW YORK NY 10013 NEW YORK HOSP,CORNELL MED CTR,DEPT CLIN BIOCHEM NEW YORK NY 10021 NYU,SCH MED NEW YORK NY 00000
Titolo Testata:
American journal of health-system pharmacy
fascicolo: 11, volume: 55, anno: 1998,
pagine: 1134 - 1140
SICI:
1079-2082(1998)55:11<1134:FAPOCO>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPILEPSY; EPOXIDE; CARBAMAZEPINE-10,11-EPOXIDE; CHILDREN; PLASMA; SERUM; COMBINATION; SUSPENSION; 11-EPOXIDE; THERAPY;
Keywords:
ANTICONVULSANTS; BLOOD LEVELS; CARBAMAZEPINE; CARBAMAZEPINE-10,11-EPOXIDE; DOSAGE; DOSAGE SCHEDULES; EQUIVALENCY; EXCRETION; HALF-LIFE; METABOLISM; PHARMACOKINETICS; SUSPENSIONS; TABLETS; TOXICITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
H. Cohen et al., "FEASIBILITY AND PHARMACOKINETICS OF CARBAMAZEPINE ORAL LOADING DOSES", American journal of health-system pharmacy, 55(11), 1998, pp. 1134-1140

Abstract

The pharmacokinetics and adverse effects of an oral loading dose of carbamazepine administered in tablet or suspension form were studied. Patients on a hospital epilepsy unit who were to receive carbamazepine as a discharge medication were randomly assigned to receive either an oral 8-mg/kg loading dose of the tablet formulation or the same dose of the suspension on an empty stomach. Blood samples were drawn before and at intervals up to 12 hours after the loading dose. Adverse effects were evaluated subjectively and objectively. Total and free serum carbamazepine and carbamazepine-10,11-epoxide (CBZE) concentration were determined by high-performance liquid chromatography. Six adult patients were enrolled in and completed the study. All the patients achievedtherapeutic total carbamazepine levels; the suspension group did so within two hours and the tablet group within five hours. Maximum serum carbamazepine concentrations ranged from 7.10 to 9.92 mg/L, area underthe concentration-versus-time curve from 54.85 to 82.23 mu g.hr/L, and terminal elimination half-life from 14.05 to 15.71 hours. Adverse effects were mild, few, and short-lived; none of the patients developed gastrointestinal toxicity. Adverse effects were not associated with total or free carbamazepine and CBZE concentrations or with total or free CBZE:carbamazepine ratios. An oral loading dose of carbamazepine 8 mg/kg achieved therapeutic levels within two hours when given as a suspension and within five hours when given as tablets and was well tolerated in all patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 20:24:17